Catalog

CC-20

Version 1.0

A Stepwise Approach to Acid-Base Results

Apply a six-step worksheet to acid-base results, assess compensation, and recognize when specimen, method, or mixed-process uncertainty prevents a simple label.

CC-03

Version 1.0

Accuracy, Precision, Bias, and Measurement Uncertainty

A working method for describing why repeated results differ: separate imprecision (spread) from bias (closeness to a target), calculate mean, SD, and %CV, compare a result against an allowable-difference criterion, and state what a measurement uncertainty estimate does and does not claim.

CC-07

Version 1.0

Adrenal and Pituitary Laboratory Assessment

Cortisol, ACTH, prolactin, and growth hormone/IGF-1 results require timing and context. Interpret cortisol against its circadian pattern; pair ACTH with same-draw cortisol and its own preanalytical path; distinguish the questions posed by stimulation and suppression testing; and account for medication, illness, and assay factors that can turn a technically valid result into a misleading one.

CC-19

Version 1.0

Blood Gas Fundamentals

Learn which arterial blood gas values an analyzer directly measures with dedicated electrodes, which values it calculates, how co-oximetry works as a separate measurement, and how specimen type and handling defects change results before they ever reach the electrode.

CC-12

Version 1.0

Calcium, Phosphate, PTH, and Vitamin D

Integrate total calcium, albumin, ionized calcium, phosphate, magnesium, parathyroid hormone (PTH), and vitamin D markers into one interpretable pattern, and recognize when a total or corrected calcium result may not reflect the physiologically active fraction.

CC-02

Version 1.0

Calibration and Analytical Measurement Systems

How a laboratory establishes and verifies the relationship between instrument signal and assigned analyte value, why calibration, calibration verification, and quality control are three distinct activities, and what a technologist does when a calibration signal drifts.

CC-18

Version 1.0

Connecting Renal Chemistry with Urinalysis

Integrate eGFR, urine albumin and protein ratios, dipstick chemistry, sediment cells, and casts into a bounded kidney-injury pattern while recognizing discordance requiring repeat, confirmation, or local-policy escalation.

CC-17

Version 1.0

Creatinine, Cystatin C, and Estimated GFR

Creatinine and cystatin C are filtration markers, not direct measurements of glomerular filtration rate. Each marker is generated and handled by the kidney differently, the current race-free CKD-EPI equations require specific inputs, and a single eGFR is likely to mislead during acute kidney change, extremes of muscle mass, diet, pregnancy, in children, and during transplant evaluation. A paired creatinine-only and creatinine-cystatin C calculation walks through to a bench decision.

CC-26

Version 1.0

Drug Metabolism and Toxicology Methods

Interpret toxicology findings by connecting specimen selection, metabolism, screening design, confirmation, and the purpose of the cutoff.

CC-08

Version 1.0

Estradiol and the Hypothalamic-Pituitary-Gonadal Axis

Interpret a serum estradiol result against the hypothalamic-pituitary-gonadal (HPG) feedback loop, cycle phase, life stage, sex, and medication context, and recognize where immunoassay measurement runs out of low-end reliability.

CC-30

Version 1.0

Heavy Metals, Trace Elements, and Selected Toxins

Select contamination-controlled specimens and interpret trace-element results by matrix, timing, species, and analytical method.

CC-01

Version 1.1

How an Analyzer Produces a Result

Trace a chemistry result from specimen aspiration through signal generation, calculation, flags, and verified release, and learn where an otherwise plausible number can become unreliable before it ever fails a QC rule.

CC-16

Version 1.0

How Lipid-Lowering Therapy Changes Laboratory Results

Common lipid-lowering drug classes change lipid panel and safety-monitoring results in identifiable patterns. Separating an expected treatment response from nonadherence, biological variation, and analytical or method problems lets a delayed or internally inconsistent lipid trend get verified before it is read as a treatment effect.

CC-13

Version 1.0

Laboratory Assessment of Bone Health and Osteoporosis

How mineral homeostasis testing and bone-turnover markers support, but never replace, the DXA-based diagnosis of osteoporosis, with a guided case on collection timing and serial comparability.

CC-09

Version 1.0

Laboratory Diagnosis of Diabetes

Work through which laboratory findings can establish diabetes or increased glycemic risk in a nonpregnant adult, when a single abnormal result is enough versus when confirmation is required, and which specimen, hemoglobin, and assay conditions can make a criterion unreliable.

CC-11

Version 1.0

Metabolic Syndrome and Continuous Glucose Monitoring

Place fasting glucose, lipids, and CGM-derived metrics into a metabolic-risk picture, learn which criteria version and glucose threshold a metabolic-syndrome classification depends on, and interpret an ambulatory glucose profile with attention to sensor data sufficiency and the difference between GMI and laboratory A1c.

CC-10

Version 1.0

Monitoring Diabetes: Glucose, A1c, and Their Limitations

A working guide to reconciling spot glucose, serial or self-monitored glucose, A1c, fructosamine/glycated albumin, and CGM summaries when they describe the same patient differently. Covers the time window each measure represents, the biological and analytical causes of A1c-glucose mismatch, and how to frame a bounded laboratory communication when the numbers disagree.

CC-21

Version 1.0

Oxygen Transport and the Oxyhemoglobin Dissociation Curve

Interpret oxygen tension, saturation, hemoglobin fractions, and arterial oxygen content as related but distinct laboratory information.

CC-29

Version 1.0

Pharmacogenomics for the Laboratory Professional

Follow a pharmacogenomic result from a detected variant through diplotype and predicted phenotype to a bounded, current report.

CC-31

Version 1.0

Preeclampsia Testing and Emerging Biomarkers

Use routine laboratory evidence and a bounded, assay-specific angiogenic biomarker result to support evaluation of suspected preeclampsia without turning a risk assay into a diagnosis.

CC-22

Version 1.0

Protein Electrophoresis and Pattern Recognition

Recognize serum and urine protein electrophoresis patterns, identify look-alikes, and select bounded laboratory follow-up.

CC-15

Version 1.0

Reading a Lipid Panel

Interpret a standard lipid panel by separating what the analyzer measures from what is calculated, verify the calculation behind LDL-C and non-HDL-C, and recognize when triglycerides are too high for a calculated LDL-C result to be reported.

CC-05

Version 1.0

Reading an Endocrine Feedback Loop

A stimulating hormone and its target-gland hormone travel together as a pair, not as two independent numbers. The negative-feedback model behind that pair shows how the direction of both values localizes a problem to the target gland versus the pituitary or hypothalamus; timing, binding-protein, illness, and assay-interference factors can make that pattern mislead a reader who has not checked the context behind the numbers.

CC-04

Version 1.0

Sensitivity, Specificity, and Specimen Interference

A method's ability to detect a measurand and a test's ability to diagnose a condition are two different questions, and a flagged or unflagged specimen does not settle either one by itself. Limit of blank, limit of detection, and limit of quantitation differ from diagnostic sensitivity, specificity, and predictive value. Hemolysis, biotin, and heterophile antibody interference can require a defensible next step for a discordant result.

CC-24

Version 1.0

Sepsis Biomarkers: Uses and Limitations

Use lactate, procalcitonin, CRP, culture timing, and evidence labels as time-dependent adjuncts without turning any single result into a sepsis diagnosis.

CC-14

Version 1.0

Serial Cardiac Biomarkers and Myocardial Injury

Work through how to read serial high-sensitivity cardiac troponin (hs-cTn) results: what the assay-specific 99th-percentile upper reference limit (URL) means, how a rise or fall pattern distinguishes acute from chronic myocardial injury, how the ESC 0h/1h sampling algorithm classifies a patient into rule-out, observe, or rule-in zones, and how to recognize nonischemic causes and analytical interferents such as macrotroponin before a discordant result is escalated.

CC-23

Version 1.0

The Laboratory Role in Cystic Fibrosis Testing

Use newborn-screening, sweat chloride, and CFTR molecular results as distinct evidence streams while protecting sweat specimen adequacy and reporting uncertainty clearly.

CC-27

Version 1.0

Therapeutic Drug Monitoring

Evaluate whether a therapeutic drug concentration was collected at the right time and can answer the monitoring question.

CC-06

Version 1.0

Thyroid Testing as a Pattern

A TSH result comes back suppressed with no free T4 measured yet. The pattern-recognition framework for TSH, free T4, total T4/T3, and thyroid antibody results covers classifying primary versus central hypo- and hyperthyroid directions, recognizing when total and free hormone can legitimately disagree, and knowing when biotin, heterophile antibodies, macro-TSH, or nonthyroidal illness should stop a diagnostic statement rather than support one.

CC-25

Version 1.0

Tumor Markers: What They Can and Cannot Tell You

Use tumor-marker results by purpose, serial pattern, and method context. Recognize why an abnormal result supports a clinical question but rarely establishes cancer.

CC-28

Version 1.0

Urine Drug and Opiate Testing

Interpret urine drug-testing patterns by assay target, metabolites, specimen validity, cutoff, and confirmation status.